Show simple item record

Monitoramento do cumprimento do protocolo clínico e diretrizes terapêuticas da doença de alzheimer.

dc.contributor.authorForgerini, Marcela [UNESP]
dc.contributor.authorMastroianni, Patrícia de Carvalho [UNESP]
dc.date.accessioned2020-12-12T01:58:41Z
dc.date.available2020-12-12T01:58:41Z
dc.date.issued2020-01-01
dc.identifierhttp://dx.doi.org/10.1590/1980-57642020dn14-010004
dc.identifier.citationDementia e Neuropsychologia, v. 14, n. 1, p. 24-27, 2020.
dc.identifier.issn1980-5764
dc.identifier.urihttp://hdl.handle.net/11449/200137
dc.description.abstractDementia is a chronic neurodegenerative disease and Alzheimer’s disease (AD) is the most prevalent type. Objective: To describe the drug monitoring of patients enrolled in a Clinical Protocol and Therapeutic Guidelines of Alzheimer’s Disease (PCDTDA) in Brazil. Methods: A descriptive study based on interviews conducted in 2017 was performed. Patients diagnosed with Alzheimer’s disease (AD) enrolled on the PCDTDA were included. The variables assessed were age, sex, time since diagnosis, clinical parameters of Mini-Mental State Exam (MMSE) and Clinical Dementia Rating (CDR), drug therapy used and AD drug collection. Results: The drug monitoring of 143 patients was evaluated. Observing the requirements of the screening tests for patient enrolment on the PCDTDA, all patients had scores for at least one MMSE and CDR assessment at protocol admission. None of the patients underwent the first reassessment of the effectiveness of AD drug therapy or the semiannual reassessment. Conclusion: Although PCDTDA provides the best evidence of AD treatment, the data showed failures in the monitoring of the effectiveness of AD drug therapy at dispensing.en
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.format.extent24-27
dc.language.isoeng
dc.relation.ispartofDementia e Neuropsychologia
dc.sourceScopus
dc.subjectClinical protocols
dc.subjectDementia
dc.subjectDrug monitoring
dc.subjectDrug safety
dc.subjectPatient safety
dc.titleMonitoring compliance with clinical protocol and therapeutic guidelines for alzheimer’s diseaseen
dc.titleMonitoramento do cumprimento do protocolo clínico e diretrizes terapêuticas da doença de alzheimer.pt
dc.typeArtigo
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.description.affiliationSchool of Pharmaceutical Sciences Department of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationSão Paulo State University (UNESP) Department of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationUnespSchool of Pharmaceutical Sciences Department of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationUnespSão Paulo State University (UNESP) Department of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.identifier.doi10.1590/1980-57642020dn14-010004
dc.identifier.scieloS1980-57642020000100024
dc.rights.accessRightsAcesso aberto
dc.description.sponsorshipIdCAPES: 001
dc.description.sponsorshipIdCNPq: 131206/2017-6
dc.description.sponsorshipIdFAPESP: 2018/07501-9
dc.description.sponsorshipIdCNPq: 459461/2014-1
dc.identifier.scopus2-s2.0-85081228267
dc.identifier.fileS1980-57642020000100024.pdf
Localize o texto completo

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record